PROS1 and prostate carcinoma: Prostate-specific antigen (PSA) is a US Food and Drug Administration (FDA)-approved serum biomarker for prostate cancer (PCa) screening, and its glycosylation profiles in PCa patients provide the potential for improving the specificity of the PSA test [131,132].